Jack L. Wyszomierski Sells 8,768 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Jack L. Wyszomierski sold 8,768 shares of the company’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the sale, the director now directly owns 356,605 shares in the company, valued at approximately $13,479,669. The trade was a 2.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Exelixis Stock Performance

NASDAQ EXEL opened at $38.69 on Friday. The firm has a market capitalization of $10.83 billion, a price-to-earnings ratio of 21.86, a PEG ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a one year low of $20.14 and a one year high of $38.72. The company’s 50 day moving average price is $34.53 and its 200 day moving average price is $31.62.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Sell-side analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 19th. Citigroup lifted their price target on shares of Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Brookline Capital Management assumed coverage on shares of Exelixis in a research report on Monday, December 23rd. They issued a “buy” rating for the company. Stifel Nicolaus raised their target price on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research report on Wednesday, February 12th. Finally, Piper Sandler boosted their price target on Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $37.24.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Coppell Advisory Solutions LLC acquired a new stake in shares of Exelixis in the fourth quarter valued at about $25,000. Colonial Trust Co SC boosted its holdings in Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 765 shares during the period. USA Financial Formulas acquired a new stake in Exelixis in the fourth quarter valued at approximately $32,000. Principal Securities Inc. raised its stake in shares of Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 373 shares during the period. Finally, Kestra Investment Management LLC acquired a new position in shares of Exelixis during the fourth quarter worth $39,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.